Belyntic
Berlin
About Belyntic
Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.8M
- Funding stage: M&A
- Last round: Non-Equity Assistance (Nov 2021)
- Website: belyntic.com
- Phone: +49 (0)30 166 34 54 55
Industries & Categories
Biotechnology, Health Care, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/belyntic-112791 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.